| scholarly article | Q13442814 |
| P50 | author | Peter S Oturai | Q44862934 |
| Jann Mortensen | Q50549404 | ||
| Søren Holm | Q20984761 | ||
| Liselotte Højgaard | Q28520613 | ||
| Andreas Kjær | Q39183738 | ||
| P2093 | author name string | Palle Rasmussen | |
| Ulrich Knigge | |||
| Annika Loft | |||
| Eric von Benzon | |||
| Andreas Pfeifer | |||
| Tina Binderup | |||
| Thomas Levin Klausen | |||
| Anne Kiil Berthelsen | |||
| Dennis Elema | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1207-1215 | |
| P577 | publication date | 2012-07-10 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study | |
| P478 | volume | 53 |
| Q36568335 | (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2 |
| Q89946986 | 64Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms |
| Q35777600 | 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy |
| Q93159938 | 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy |
| Q38749965 | A Modular Dual Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. |
| Q33700120 | A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers |
| Q55006457 | Advancing theranostics with tumor-targeting peptides for precision otolaryngology. |
| Q34107681 | Blood transcript analysis and metastatic recurrent small bowel carcinoid management |
| Q42925462 | Cancer theranostics with ⁶⁴Cu/¹⁷⁷Lu-loaded liposomes |
| Q57484995 | Copper-64: a real theranostic agent |
| Q28071483 | Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours |
| Q50911560 | Establishing Reliable Cu-64 Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging. |
| Q36191589 | First-in-human uPAR PET: Imaging of Cancer Aggressiveness |
| Q48089118 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. |
| Q34992753 | Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q55226872 | Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. |
| Q26824070 | Mapping biological behaviors by application of longer-lived positron emitting radionuclides |
| Q35756123 | Measured human dosimetry of 68Ga-DOTATATE. |
| Q39016753 | Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management |
| Q40986557 | Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector |
| Q26768483 | Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review |
| Q38771260 | Neuroendocrine, goblet cell and mixed adeno-neuroendocrine tumours of the appendix: updates, clinical applications and the future |
| Q38241601 | Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms |
| Q39066068 | PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate |
| Q26992201 | PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature |
| Q39498230 | PET/MRI in cancer patients: first experiences and vision from Copenhagen |
| Q33746948 | Pilot Study of 64Cu(I) for PET Imaging of Melanoma |
| Q26996521 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids |
| Q44630094 | Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q38175261 | Recommendations for management of patients with neuroendocrine liver metastases |
| Q42133416 | Somatostatin analogues labeled with copper radioisotopes: current status. |
| Q95360903 | Somatostatin receptor PET ligands - the next generation for clinical practice |
| Q38123057 | Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis |
| Q42548064 | Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors |
| Q33661508 | The copper radioisotopes: a systematic review with special interest to 64Cu |
| Q48827044 | The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever.... |
| Q26865306 | Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications |
| Q38469898 | Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors |
| Q40991225 | VPAC1 receptors for imaging breast cancer: a feasibility study |
Search more.